Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that an update on the DIAMOND Phase 3 program with OCS-01, an OPTIREACH® formulation of high concentration dexamethasone eye drop, for diabetic macular edema (DME) will be presented by David Eichenbaum, M.D. at Innovate Retina. In addition, Riad Sherif, M.D., Oculis' Chief Executive Officer, will be presenting at Eyecelerator 2024, ahead of the American Academy of Ophthalmology Annual Meeting where Oculis will be exhibiting (booth 5452).
Both presentations from Dr. Eichenbaum and Dr. Sherif will highlight the robust results with OCS-01 eye drops in DME from Stage 1 of the DIAMOND program at Week 12 and will present the design of Stage 2 to assess the efficacy and safety of OCS-01 eye drops for the treatment of DME at Week 52. Both Phase 3 trials (DIAMOND-1 and DIAMOND-2) are ongoing and aim to enroll 350 patients each.
Furthermore, Dr. Sherif's presentation will highlight upcoming near-term milestones, including the topline results from the ACUITY Phase 2 trial with OCS-05 for the treatment of acute optic neuritis, anticipated before the end of 2024.
Eyecelerator 2024
Format: Corporate presentation
Session: Retina Showcase
Presenter: Riad Sherif, MD, Chief Executive Officer
Presentation date and time: October 17, 2024 at 2:06 pm CT
Location: McCormik Place, Chicago, IL
Innovate Retina
Presentation title: OCS-01: novel topical approach for macular edema
Session: New Routes and New Molecules
Presenter: David Eichenbaum, MD
Presentation date and time: October 17, 2024 at 5:31 pm CT
Location: InterContinental Chicago Magnificent Mile, Chicago, IL
David Eichenbaum, M.D. is a board-certified ophthalmologist, fellowship-trained in diseases and surgery of the vitreous and retina and he is a Partner and Director of Research at Retina Vitreous Associates of Florida. Dr. Eichenbaum has served as Principal Investigator in over 90 Phase 1 though Phase 4 clinical trials and has published over 70 articles in professional journals, published multiple textbook chapters and regularly presents his work in scientific congresses. He also serves on numerous Clinical and Scientific Advisory Boards and National Executive Steering Committees for both commercial and pipeline products. Dr. Eichenbaum completed the Medical Honors Program at the University of South Florida, earning his undergraduate and medical degree in Tampa. He completed his Ophthalmology residency at the University of South Florida, where he served as Chief Resident, and completed his two-year Surgical Retina fellowship at Tufts New England Eye Center and Ophthalmic Consultants of Boston.